⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AUTL News
Autolus Therapeutics plc American Depositary Share
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
globenewswire.com
AUTL
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
globenewswire.com
AUTL
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
globenewswire.com
AUTL
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
globenewswire.com
AUTL
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
globenewswire.com
AUTL
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
globenewswire.com
AUTL
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
globenewswire.com
AUTL
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025
globenewswire.com
AUTL
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
AUTL
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
prnewswire.com
IOBT
SRPT
AUTL
ARCT
IOBT
SRPT
AUTL
ARCT